EVAX

Evaxion A/S

Price Chart

Latest Quote

$3.24

+0.19 (+6.23%)

Current Price

Previous Close	$3.05
Open	$3.14
Day High	$3.25
Day Low	$3.02
Volume	17,865

Fetched: 2026-06-22T14:55:48

Stock Information

Shares Outstanding	8.34M
Cash Equivalents	$18.44M
Revenue	$7.53M
Net Income	$-9.76M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$27.02M
EPS (TTM)	$-1.00
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$7.00M
Sales	$7.53M
Income	$-9.76M
Book/sh	$1.58
Cash/sh	$2.21
Employees	46

Financial Ratios

Returns & Margins

ROA	-23.49%
ROE	-82.93%
Gross Margin	100.00%
Operating Margin	-122.01%
Profit Margin	-129.60%

Ownership

Insider Ownership	17.47%
Institutional Ownership	9.05%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	81.00
P/S	3.59
P/B	2.05

Analyst Data

Recommendation	none
Target Price	$11.25

Technical Indicators

SMA20	$3.70
SMA50	$4.02
SMA200	$4.46
RSI	36.48
ATR	0.3118

Shares Float	5.68M
Short Float	0.36%
Short Ratio	0.90
Volatility	0.23
Rel Volume	0.53

Performance History

Week	-10.99%
Month	-19.00%
Quarter	-17.14%
6 Months	-44.71%
YTD	-31.21%
Year	+49.31%
3 Years	-95.02%
5 Years	-99.02%
10 Years	-99.34%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$3.24	17,865
2026-06-18	$3.05	42,500
2026-06-17	$3.32	30,900
2026-06-16	$3.42	33,400
2026-06-15	$3.60	28,900
2026-06-12	$3.64	58,900
2026-06-11	$3.61	16,400
2026-06-10	$3.79	25,000
2026-06-09	$3.63	28,300
2026-06-08	$3.73	20,300
2026-06-05	$3.55	58,000
2026-06-04	$3.87	57,500
2026-06-03	$3.54	19,600
2026-06-02	$3.75	43,600
2026-06-01	$3.90	35,700
2026-05-29	$4.00	19,100
2026-05-28	$4.10	8,800
2026-05-27	$4.05	86,200
2026-05-26	$4.11	18,400
2026-05-22	$4.08	24,800

About Evaxion A/S

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires • 2026-06-12T15:14:33Z

European Equities Traded in US as ADRs Rise in Thursday Trading

MT Newswires • 2026-06-11T15:09:49Z

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

MT Newswires • 2026-06-10T15:07:47Z

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires • 2026-06-08T15:10:25Z

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-06-04T15:08:32Z

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

MT Newswires • 2026-06-03T15:10:58Z

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires • 2026-06-01T15:11:54Z

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires • 2026-05-18T15:11:28Z

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

MT Newswires • 2026-05-13T15:12:40Z

European Equities Traded in the US as American Depositary Receipts Rise Friday

MT Newswires • 2026-05-08T15:10:04Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$7,528,000	$3,344,000	$73,000	$0
Operating Revenue	$7,528,000	$3,344,000	$73,000	$0
Expenses
Interest Expense	$876,000	$962,000	$897,000	$798,000
Total Expenses	$16,762,000	$18,076,000	$22,270,000	$25,264,000
Other Income Expense	$-1,372,000	$4,085,000	$25,000	$2,108,000
Net Non Operating Interest Income Expense	$1,991,000	$-708,000	$-743,000	$-785,000
Total Other Finance Cost	$-2,568,000	-	-	-
Interest Expense Non Operating	$876,000	$962,000	$897,000	$798,000
Operating Expense	$16,762,000	$18,076,000	$22,270,000	$25,264,000
General And Administrative Expense	$6,486,000	$7,317,000	$10,079,000	$8,064,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Net Interest Income	$1,991,000	$-708,000	$-743,000	$-785,000
Interest Income	$299,000	$254,000	$154,000	$13,000
Normalized Income	$-6,472,200	$-14,366,050	$-22,149,000	$-25,192,680
Net Income From Continuing And Discontinued Operation	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Total Operating Income As Reported	$-9,234,000	$-14,732,000	$-22,197,000	$-25,264,000
Net Income Common Stockholders	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Net Income	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Net Income Including Noncontrolling Interests	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Net Income Continuous Operations	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Pretax Income	$-8,615,000	$-11,355,000	$-22,915,000	$-23,941,000
Interest Income Non Operating	$299,000	$254,000	$154,000	$13,000
Operating Income	$-9,234,000	$-14,732,000	$-22,197,000	$-25,264,000
Depreciation Amortization Depletion Income Statement	$301,000	$302,000	$275,000	$144,000
Depreciation And Amortization In Income Statement	$301,000	$302,000	$275,000	$144,000
Depreciation Income Statement	$301,000	$302,000	$275,000	$144,000
Per Share
Diluted EPS	$-1.00	$-10.00	$-40.50	$-49.00
Basic EPS	$-1.00	$-10.00	$-40.50	$-49.00
Other
Tax Effect Of Unusual Items	$-137,200	$285,950	$1,000	$84,320
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-5,752,000	$-13,871,000	$-21,428,000	$-24,680,000
Total Unusual Items	$-1,372,000	$4,085,000	$25,000	$2,108,000
Total Unusual Items Excluding Goodwill	$-1,372,000	$4,085,000	$25,000	$2,108,000
Reconciled Depreciation	$615,000	$607,000	$615,000	$571,000
EBITDA (Bullshit earnings)	$-7,124,000	$-9,786,000	$-21,403,000	$-22,572,000
EBIT	$-7,739,000	$-10,393,000	$-22,018,000	$-23,143,000
Diluted Average Shares	$6,408,128	$1,072,890	$546,717	$472,774
Basic Average Shares	$6,408,128	$1,072,890	$546,717	$472,774
Diluted NI Availto Com Stockholders	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Tax Provision	$-908,000	$-788,000	$-790,000	$-772,000
Gain On Sale Of Security	$-1,372,000	$4,085,000	$25,000	$2,108,000
Research And Development	$9,975,000	$10,457,000	$11,916,000	$17,056,000
Selling General And Administration	$6,486,000	$7,317,000	$10,079,000	$8,064,000
Other Gand A	$3,812,000	$4,729,000	$6,947,000	$5,899,000
Salaries And Wages	$2,674,000	$2,588,000	$3,132,000	$2,165,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$17,039,000	$-1,652,000	$-4,729,000	$8,303,000
Total Assets	$28,408,000	$12,485,000	$12,889,000	$22,025,000
Total Non Current Assets	$3,507,000	$3,720,000	$4,539,000	$5,040,000
Non Current Prepaid Assets	$185,000	$162,000	$167,000	$156,000
Current Assets	$24,901,000	$8,765,000	$8,350,000	$16,985,000
Prepaid Assets	$616,000	$955,000	$1,692,000	$2,494,000
Receivables	$1,051,000	$1,858,000	$1,075,000	$1,307,000
Taxes Receivable	$1,051,000	$1,756,000	$958,000	$1,076,000
Cash Cash Equivalents And Short Term Investments	$23,234,000	$5,952,000	$4,183,000	$13,184,000
Cash And Cash Equivalents	$23,234,000	$5,952,000	$4,183,000	$13,184,000
Non Current Accounts Receivable	-	$44,000	$29,000	$209,000
Restricted Cash	-	$900,000	$1,400,000	-
Other Receivables	-	$102,000	$117,000	$231,000
Goodwill And Other Intangible Assets	-	-	-	$0
Non Current Deferred Assets	-	-	-	-
Non Current Deferred Taxes Assets	-	-	-	-
Current Deferred Assets	-	-	-	-
Debt
Total Debt	$7,504,000	$10,101,000	$10,870,000	$10,255,000
Long Term Debt And Capital Lease Obligation	$6,954,000	$9,628,000	$10,385,000	$9,816,000
Long Term Debt	$5,347,000	$8,008,000	$8,489,000	$7,864,000
Current Debt And Capital Lease Obligation	$550,000	$473,000	$485,000	$439,000
Current Debt	$190,000	$159,000	$159,000	$136,000
Other Current Borrowings	$190,000	$159,000	$159,000	$136,000
Net Debt	-	$2,215,000	$4,465,000	-
Liabilities
Total Liabilities Net Minority Interest	$11,369,000	$14,137,000	$17,618,000	$13,722,000
Total Non Current Liabilities Net Minority Interest	$7,112,000	$9,769,000	$10,534,000	$9,960,000
Current Liabilities	$4,257,000	$4,368,000	$7,084,000	$3,762,000
Other Current Liabilities	$416,000	$67,000	$3,016,000	$885,000
Payables And Accrued Expenses	$2,186,000	$2,968,000	$2,689,000	$2,085,000
Payables	$2,186,000	$2,968,000	$2,689,000	$2,085,000
Accounts Payable	$2,186,000	$2,968,000	$2,689,000	$2,085,000
Other Non Current Liabilities	-	-	$10,000	-
Other Payable	-	-	-	$312,000
Equity
Common Stock Equity	$17,039,000	$-1,652,000	$-4,729,000	$8,303,000
Total Equity Gross Minority Interest	$17,039,000	$-1,652,000	$-4,729,000	$8,303,000
Stockholders Equity	$17,039,000	$-1,652,000	$-4,729,000	$8,303,000
Other Equity Interest	$9,991,000	$14,022,000	$13,665,000	$13,186,000
Gains Losses Not Affecting Retained Earnings	$-3,230,000	$-3,595,000	$-3,773,000	$-3,651,000
Retained Earnings	$-126,244,000	$-118,537,000	$-107,970,000	$-85,845,000
Other Equity Adjustments	-	-	-	-
Other
Ordinary Shares Number	$417,010,756	$70,130,556	$37,897,780	$24,139,413
Share Issued	$417,010,756	$70,130,556	$37,897,780	$24,139,413
Tangible Book Value	$17,039,000	$-1,652,000	$-4,729,000	$8,303,000
Invested Capital	$22,576,000	$6,515,000	$3,919,000	$16,303,000
Working Capital	$20,644,000	$4,397,000	$1,266,000	$13,223,000
Capital Lease Obligations	$1,967,000	$1,934,000	$2,222,000	$2,255,000
Total Capitalization	$22,386,000	$6,356,000	$3,760,000	$16,167,000
Foreign Currency Translation Adjustments	$-3,230,000	$-3,595,000	$-3,773,000	$-3,651,000
Additional Paid In Capital	$120,731,000	$95,942,000	$87,450,000	$80,727,000
Capital Stock	$15,791,000	$10,516,000	$5,899,000	$3,886,000
Common Stock	$15,791,000	$10,516,000	$5,899,000	$3,886,000
Long Term Capital Lease Obligation	$1,607,000	$1,620,000	$1,896,000	$1,952,000
Long Term Provisions	$158,000	$141,000	$149,000	$144,000
Current Capital Lease Obligation	$360,000	$314,000	$326,000	$303,000
Pensionand Other Post Retirement Benefit Plans Current	$1,105,000	$860,000	$894,000	$353,000
Net PPE	$3,322,000	$3,514,000	$4,343,000	$4,675,000
Accumulated Depreciation	$-2,202,000	$-1,534,000	$-1,166,000	$-721,000
Gross PPE	$5,524,000	$5,048,000	$5,509,000	$5,396,000
Leases	$1,134,000	$1,160,000	$1,390,000	$1,435,000
Other Properties	$4,390,000	$3,888,000	$4,119,000	$3,961,000
Properties	$0	$0	$0	$0
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-6,636,000	$-12,940,000	$-17,778,000	$-26,066,000
Operating Activities
Operating Cash Flow	$-6,625,000	$-12,940,000	$-17,691,000	$-25,774,000
Cash Flow From Continuing Operating Activities	$-6,625,000	$-12,940,000	$-17,691,000	$-25,774,000
Operating Gains Losses	-	$-3,883,000	$-282,000	$-395,000
Investing Activities
Capital Expenditure	$-11,000	-	$-87,000	$-292,000
Investing Cash Flow	$-14,000	$-3,000	$-93,000	$-268,000
Cash Flow From Continuing Investing Activities	$-14,000	$-3,000	$-93,000	$-268,000
Financing Activities
Issuance Of Capital Stock	$23,161,000	$14,206,000	$11,323,000	$428,000
Financing Cash Flow	$22,410,000	$13,129,000	$10,691,000	$7,853,000
Cash Flow From Continuing Financing Activities	$22,410,000	$13,129,000	$10,691,000	$7,853,000
Net Common Stock Issuance	$23,161,000	$14,206,000	$11,323,000	$428,000
Common Stock Issuance	$23,161,000	$14,206,000	$11,323,000	$428,000
Net Other Financing Charges	-	$59,000	$-432,000	-
Other
Repayment Of Debt	$-751,000	$-1,136,000	$-697,000	$-424,000
Issuance Of Debt	$0	$0	$65,000	$7,849,000
End Cash Position	$23,234,000	$5,952,000	$5,583,000	$13,184,000
Beginning Cash Position	$5,952,000	$5,583,000	$13,184,000	$32,166,000
Effect Of Exchange Rate Changes	$1,511,000	$183,000	$-508,000	$-793,000
Changes In Cash	$15,771,000	$186,000	$-7,093,000	$-18,189,000
Net Issuance Payments Of Debt	$-751,000	$-1,136,000	$-632,000	$7,425,000
Net Long Term Debt Issuance	$-751,000	$-1,136,000	$-632,000	$7,425,000
Long Term Debt Payments	$-751,000	$-1,136,000	$-697,000	$-424,000
Long Term Debt Issuance	$0	$0	$65,000	$7,849,000
Net Investment Purchase And Sale	$-3,000	$-3,000	$-6,000	$24,000
Purchase Of Investment	$-3,000	$-3,000	$-6,000	-
Net PPE Purchase And Sale	$-11,000	$0	$-87,000	$-292,000
Purchase Of PPE	$-11,000	$0	$-87,000	$-292,000
Taxes Refund Paid	$1,632,000	$0	$1,597,000	$754,000
Interest Received Cfo	$299,000	$254,000	$154,000	$13,000
Interest Paid Cfo	$-107,000	$-56,000	$-65,000	$-172,000
Change In Working Capital	$-137,000	$520,000	$1,562,000	$-2,877,000
Change In Other Working Capital	$-185,000	$13,000	$-261,000	-
Change In Payables And Accrued Expense	$-536,000	$-62,000	$762,000	$-1,391,000
Change In Payable	$-536,000	$-62,000	$762,000	$-1,391,000
Change In Account Payable	$-536,000	$-62,000	$762,000	$-599,000
Change In Prepaid Assets	$406,000	$736,000	$802,000	-
Change In Receivables	$178,000	$-167,000	$259,000	$-1,486,000
Other Non Cash Items	$-619,000	$-3,242,000	$1,076,000	$-530,000
Stock Based Compensation	$307,000	$357,000	$479,000	$942,000
Deferred Tax	$-908,000	$-813,000	$-984,000	$-998,000
Deferred Income Tax	$-908,000	$-813,000	$-984,000	$-998,000
Depreciation Amortization Depletion	$615,000	$607,000	$615,000	$571,000
Depreciation And Amortization	$615,000	$607,000	$615,000	$571,000
Depreciation	$615,000	$607,000	$615,000	$571,000
Net Income From Continuing Operations	$-7,707,000	$-10,567,000	$-22,125,000	$-23,169,000
Proceeds From Stock Option Exercised	-	$0	$2,587,000	$0
Net Intangibles Purchase And Sale	-	$0	$0	$0
Purchase Of Intangibles	-	$0	$0	$0
Asset Impairment Charge	-	$0	$0	$87,000
Gain Loss On Investment Securities	-	$-3,883,000	$-282,000	$-395,000
Sale Of Investment	-	-	-	$24,000
Sale Of PPE	-	-	-	$24,000

Fetched: 2026-06-16